Allurar Tirzepatide don Ciwon sukari da Rage nauyi

Tirzepatide wani labari ne mai dogaro da insulinotropic polypeptide (GIP) da glucagon-like peptide-1 (GLP-1) agonist mai karɓa wanda aka haɓaka. Tsarin sa na biyu yana nufin haɓaka siginin insulin, danne sakin glucagon, jinkirta zubar da ciki, da haɓaka satiety, yana ba da cikakkiyar hanyar warkewa don nau'in ciwon sukari na 2 (T2DM) da kiba.

Mabuɗin Nemo daga Nazarin Nazari

1. Glycemic Control

Gaba ɗayaSURPASSlokaci 3 gwaji na asibiti, tirzepatide ya nunamafi kyawun sarrafa glycemicidan aka kwatanta da magungunan antidiabetic na yanzu, gami da semaglutide da insulin degludec.

• Ma'anar raguwar HbA1c: har zuwa-2.4%daga asali bayan makonni 40-52.

• Mafi girman adadin mahalarta da aka samuHbA1c <6.5%, saduwa ko zarce makasudin ADA.

• An sami babban ci gaba a cikin glucose na plasma mai azumi da matakan glucose na postprandial.

2. Rage nauyi

Tirzepatide akai-akai ana samarwaa asibiti ma'ana da kuma kashi-dogara nauyi asaraa duka masu ciwon sukari da marasa ciwon sukari.

• A cikin marasa lafiya na T2DM: matsakaicin rage nauyin jiki ya bambanta daga7-12 kg.

• A cikin abubuwan da ba su da kiba (gwajin SURMOUNT-1):

  • 10 MG da 15 MG allurai kai ga15-22% yana nufin asarar nauyin jiki, kwatankwacin ko ƙetare iyakokin tiyata na bariatric.

• Yawancin mahalarta sun samu aƙalla5-10%rage nauyi.

3. Inganta Ciwon zuciya

Jiyya na Tirzepatide kuma ya inganta mafi girman sigogi na rayuwa:

• Ragewaa cikin triglycerides, LDL-C, da jimlar cholesterol.

• Yana ƙaruwaHDL-C.

• Mahimmanciraguwa a cikin systolic da diastolic hawan jini.

• Haɓakawa a cikin ji na insulin da aikin β-cell.

4. Tsaro da Hakuri

Bayanan martabar aminci ya yi daidai da sauran hanyoyin kwantar da hankali na incretin:

• Mafi yawan abubuwan da ba su da kyau: bayyanar cututtuka na gastrointestinal mai sauƙi zuwa matsakaici ( tashin zuciya, amai, zawo).

• Rashin haɗarin hypoglycemia, galibi lokacin amfani da insulin ko sulfonylureas.

• Ba a sami babban damuwa na aminci da aka lura a sakamakon cututtukan zuciya ba.

5. Halayen Injiniya

Tirzepatide na musammandual receptor agonismYana haɓaka duka hanyoyin GIP da GLP-1:

• Kunna GIPyana haɓaka samar da insulin da ke dogaro da glucose kuma yana iya haɓaka metabolism na adipose.

• GLP-1 kunnawayana inganta rage cin abinci kuma yana jinkirta zubar da ciki.

• Sutasirin synergisticyana haifar da ingantacciyar sarrafa glucose tare da ingantaccen rage nauyi idan aka kwatanta da wakilai guda ɗaya.

Kammalawa

Tirzepatide yana wakiltar anasara a cikin ilimin halittar jiki, bayarwaingancin da ba a taɓa gani ba a cikin sarrafa glycemic da rage nauyiga mutanen da ke da nau'in ciwon sukari na 2 da kiba.
Tsarin incretin ɗin sa na biyu yana ba da haɗin kai don magance tushen abubuwan da ke haifar da tabarbarewar rayuwa - hyperglycemia, juriya na insulin, da wuce haddi na jiki.
Ganin ingantaccen ingancin sa da bayanin martabar aminci mai iya sarrafawa, tirzepatide na iya sake fasalin yanayin warkewa don ciwon sukari da sarrafa kiba a cikin shekaru goma masu zuwa.

Magana

• Frias JP et al.,New England Journal of Medicine, 2021.

• Jastreboff AM et al.,New England Journal of Medicine, 2022 (SURMOUNT-1).

• Ludvik B et al.,Lancet, 2021.

• Bayanan Clinical Eli Lilly, Gwajin SURPASS 1-5.